The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.
The Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to grow from USD 1,464.1 Million in 2018 to USD 2,914.7 Million, Registering a CAGR of 10.50% by the end of the forecast period. As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide. The disorder is found to affect populations in all the regions of the world.
The prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment prolactin market. Strategic initiatives, mergers acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to further boost market growth during the forecast period.
Segmentation
By Drugs
- Alpha-1 Proteinase Inhibitor
- Bronchodilators
- Steroids
- Others
By Route of Administration
- Oral
- Intravenous
- Inhalation
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
Key Players
The notable players in the global Alpha-1 Antitrypsin Deficiency Treatment infusions Market include
- Kamada Pharmaceuticals (Israel)
- CSL Behring LLC (US)
- Grifols, S.A. (Spain)
- Takeda Pharmaceutical Company Limited (Japan)
- GlaxoSmithKline plc (UK)
- Boehringer Ingelheim GmbH (Germany)
- AstraZeneca (UK)
- Vectura Group plc (UK)
- Pfizer Inc. (US)
- Mylan Inc. (US)
- Others
By Region
By region, the global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East Africa (MEA).
The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1 antitrypsin deficiency treatment market is projected to be the fastest-growing during the forecast period.
Middle East Africa: The market in the Middle East Africa has been divided into the Middle East and Africa.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Market Research Future (MRFR) team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
